Rein Therapeutics Inc (RNTX)

$1.11 -0.05 (-3.90%)
Market Cap 27.19M
Revenue (ttm) 0.00
Net Income (ttm) -62.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 37,234
Avg Vol 44,580
Day's Range N/A - N/A
Shares Out 23.05M
Stochastic %K 26%
Beta 1.31
Analysts Strong Sell
Price Target $7.00

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The com...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 802 1989
Address:
12407 N. Mopac Expy., Suite 250 #390, Austin, United States
jcooptechit
jcooptechit Aug. 7 at 5:41 AM
Current Focus List: 🧐 - CAN - PROP - IPA - KODK - $RNTX - $WINT - $AIMD - $BINI ~ Traders Hub
0 · Reply
Majid74
Majid74 Aug. 2 at 12:01 PM
$RNTX https://ir.reintx.com/news-releases/news-release-details/rein-therapeutics-enters-agreements-21-million-flexible
0 · Reply
Majid74
Majid74 Aug. 2 at 9:14 AM
$RNTX News??
0 · Reply
Aburose
Aburose Aug. 1 at 10:35 PM
$RNTX next week target between 12-15
1 · Reply
Aburose
Aburose Aug. 1 at 10:23 PM
$RNTX Rein Therapeutics Enters Into Two Strategic Financing Agreements With Affiliate Of Yorkville Advisors Global, Providing Potential For Access To Up To $21M In Capital
0 · Reply
dbr_island
dbr_island Aug. 1 at 10:17 PM
There goes $RNTX VCIG is my next one Here’s why👇
0 · Reply
jcooptechit
jcooptechit Jul. 31 at 2:08 PM
Revolutionary Biotech Targeting Pancreatic Cancer. $RNTX has a 700%+ Upside Potential! 🔸FDA-cleared RenovoCath delivers 100x tumor exposure with less toxicity. 🔸TIGeR-PaC shows data of a 6-month survival boost and in Phase III. 🔸Analysts are bullish, projecting price targets up to $12. 🔸Backed by a solid $7.1M cash runway, no dilution risk, and insider buying. Communicated - Disclaimer https://stockresearchtoday.com/delivering-therapy-where-it-matters/
0 · Reply
Tunes444
Tunes444 Jul. 30 at 1:42 PM
$RNTX my thoughts exactly.
0 · Reply
DarcyF
DarcyF Jul. 30 at 1:24 PM
$RNTX
0 · Reply
MagelaMason
MagelaMason Jul. 30 at 1:23 PM
$RNTX Financing is for sure going to keep the lights on for next little while. Hopefully they can get some good results and keep the momentum going forward.
0 · Reply
Latest News on RNTX
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Jun 24, 2025, 10:11 AM EDT - 6 weeks ago

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Jun 12, 2025, 5:18 PM EDT - 2 months ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025, 7:00 AM EDT - 2 months ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025, 4:51 PM EDT - 2 months ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:09 PM EDT - 3 months ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025, 7:00 AM EDT - 3 months ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 3 months ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 3 months ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 28, 2025, 7:00 AM EDT - 3 months ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 23, 2025, 7:00 AM EDT - 3 months ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 15, 2025, 7:00 AM EDT - 4 months ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 7, 2025, 4:17 PM EDT - 4 months ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

jcooptechit
jcooptechit Aug. 7 at 5:41 AM
Current Focus List: 🧐 - CAN - PROP - IPA - KODK - $RNTX - $WINT - $AIMD - $BINI ~ Traders Hub
0 · Reply
Majid74
Majid74 Aug. 2 at 12:01 PM
$RNTX https://ir.reintx.com/news-releases/news-release-details/rein-therapeutics-enters-agreements-21-million-flexible
0 · Reply
Majid74
Majid74 Aug. 2 at 9:14 AM
$RNTX News??
0 · Reply
Aburose
Aburose Aug. 1 at 10:35 PM
$RNTX next week target between 12-15
1 · Reply
Aburose
Aburose Aug. 1 at 10:23 PM
$RNTX Rein Therapeutics Enters Into Two Strategic Financing Agreements With Affiliate Of Yorkville Advisors Global, Providing Potential For Access To Up To $21M In Capital
0 · Reply
dbr_island
dbr_island Aug. 1 at 10:17 PM
There goes $RNTX VCIG is my next one Here’s why👇
0 · Reply
jcooptechit
jcooptechit Jul. 31 at 2:08 PM
Revolutionary Biotech Targeting Pancreatic Cancer. $RNTX has a 700%+ Upside Potential! 🔸FDA-cleared RenovoCath delivers 100x tumor exposure with less toxicity. 🔸TIGeR-PaC shows data of a 6-month survival boost and in Phase III. 🔸Analysts are bullish, projecting price targets up to $12. 🔸Backed by a solid $7.1M cash runway, no dilution risk, and insider buying. Communicated - Disclaimer https://stockresearchtoday.com/delivering-therapy-where-it-matters/
0 · Reply
Tunes444
Tunes444 Jul. 30 at 1:42 PM
$RNTX my thoughts exactly.
0 · Reply
DarcyF
DarcyF Jul. 30 at 1:24 PM
$RNTX
0 · Reply
MagelaMason
MagelaMason Jul. 30 at 1:23 PM
$RNTX Financing is for sure going to keep the lights on for next little while. Hopefully they can get some good results and keep the momentum going forward.
0 · Reply
LondonLeaves9845
LondonLeaves9845 Jul. 30 at 1:21 PM
$RNTX's pipeline is focused entirely on serious, high-barrier pulmonary conditions
0 · Reply
PaoloWorld
PaoloWorld Jul. 30 at 1:20 PM
The 36-month SEPA window gives $RNTX some flexibility.
0 · Reply
StayinOuttaTheRed
StayinOuttaTheRed Jul. 30 at 1:20 PM
$RNTX
0 · Reply
Tester87100
Tester87100 Jul. 30 at 1:17 PM
$RNTX this is for sure going to keep the lights on for a while, whats their burn rate?
0 · Reply
Fearrr
Fearrr Jul. 30 at 1:16 PM
$RNTX Just saw UVI drop a video on these guys
0 · Reply
Viiinnkkaa
Viiinnkkaa Jul. 30 at 1:14 PM
$RNTX Following this one!
0 · Reply
IsaacP2
IsaacP2 Jul. 30 at 1:12 PM
$RNTX
0 · Reply
ThoughtsOnThis
ThoughtsOnThis Jul. 30 at 1:11 PM
$RNTX positioning itself in orphan pulmonary/fibrosis space with a dual-mechanism peptide in Phase 2. New financing could give them room to run trial milestones through 2026.
0 · Reply
Ferg500
Ferg500 Jul. 30 at 1:11 PM
$RNTX Rein’s LTI-03 already has Orphan Drug Designation in the U.S., and LTI-01 has Fast Track + ODD status in both U.S. and EU
0 · Reply
BigRodddd
BigRodddd Jul. 30 at 1:06 PM
$RNTX Thank you Stas!
0 · Reply
Fidely
Fidely Jul. 30 at 1:06 PM
With the new funding in place, looks like $RNTX is planning to accelerate both its IPF trial and additional R&D work across its pipeline. Watching to see if there’s more movement on LTI-01 too.
0 · Reply
LebronBOOM
LebronBOOM Jul. 30 at 1:06 PM
$RNTX dropped an 8-K filing related to this funding. If you're tracking their cash runway and clinical plans, worth a read.
0 · Reply